Novartis AG (NYSE:NVS) shares saw strong trading volume on Thursday . 3,182,976 shares were traded during trading, an increase of 163% from the previous session’s volume of 1,210,165 shares.The stock last traded at $78.20 and had previously closed at $78.77.

NVS has been the topic of a number of analyst reports. Vetr upgraded shares of Novartis AG from a “buy” rating to a “strong-buy” rating and set a $85.00 price objective on the stock in a report on Wednesday, May 4th. Zacks Investment Research upgraded shares of Novartis AG from a “sell” rating to a “hold” rating in a report on Wednesday, June 15th. Bank of America Corp. restated a “hold” rating on shares of Novartis AG in a report on Wednesday, May 18th. Citigroup Inc. restated a “neutral” rating on shares of Novartis AG in a report on Wednesday, May 18th. Finally, JPMorgan Chase & Co. restated a “buy” rating on shares of Novartis AG in a report on Tuesday, July 19th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $91.20.

The stock has a 50-day moving average of $81.80 and a 200 day moving average of $77.67. The firm has a market cap of $186.38 billion and a P/E ratio of 27.94.

Novartis AG (NYSE:NVS) last released its quarterly earnings data on Tuesday, July 19th. The company reported $1.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.18 by $0.05. The business had revenue of $12.47 billion for the quarter, compared to analysts’ expectations of $12.33 billion. During the same quarter in the prior year, the firm earned $1.25 earnings per share. On average, analysts anticipate that Novartis AG will post $4.73 earnings per share for the current fiscal year.

Novartis AG is a holding company. The Company specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. Its portfolio includes medicines, eye care and generic pharmaceuticals. The Company’s segments include Pharmaceuticals, Alcon and Sandoz.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.